CFTR and cystic fibrosis: Lastly, our siRNA study (Figs 2 and S3) and animal heterozygosity (Figs 4 and S6), where DNAJB9 mRNA were only partially downregulated, suggesting that DNAJB9 might be a limiting factor in CFTR ERAD pathway and that targeting DNAJB9 using specific inhibitor may turn out to be an important strategy in correcting Cystic Fibrosis effectively.